78 search results for Caspase-9
| # | SuperPathway Name | Genes Count | Relevance Score | |||
|---|---|---|---|---|---|---|
| 1 | Programmed Cell Death | 213 | 0.521 | |||
|
||||||
| 2 | MTHFR deficiency | 21 | 0.521 | |||
|
||||||
| 3 | Apoptosis and Autophagy | 185 | 0.521 | |||
|
||||||
| 4 | DNA IR-double strand breaks and cellular response via ATM | 65 | 0.521 | |||
|
||||||
| 5 | Small cell lung cancer | 96 | 0.521 | |||
|
||||||
| 6 | Development VEGF signaling via VEGFR2 - generic cascades | 147 | 0.521 | |||
|
||||||
| 7 | Alzheimer's disease and miRNA effects | 267 | 0.521 | |||
|
||||||
| 8 | PIP3 activates AKT signaling | 310 | 0.521 | |||
|
||||||
| 9 | Death Receptor Signaling Pathway | 119 | 0.521 | |||
|
||||||
| 10 | Complement cascade | 176 | 0.521 | |||
|
||||||
| 11 | Autophagy pathway | 228 | 0.521 | |||
|
||||||
| 12 | Host-pathogen interaction of human coronaviruses - apoptosis | 21 | 0.521 | |||
|
||||||
| 13 | Akt Signaling | 682 | 0.521 | |||
|
||||||
| 14 | Acute viral myocarditis | 75 | 0.521 | |||
|
||||||
| 15 | VEGF Pathway (Tocris) | 58 | 0.521 | |||
|
||||||
| 16 | Amyotrophic lateral sclerosis (ALS) | 36 | 0.521 | |||
|
||||||
| 17 | Parkinson's disease pathway | 38 | 0.521 | |||
|
||||||
| 18 | PAK Pathway | 686 | 0.521 | |||
|
||||||
| 19 | Apoptosis and survival FAS signaling cascades | 108 | 0.521 | |||
|
||||||
| 20 | Constitutive Signaling by AKT1 E17K in Cancer | 38 | 0.521 | |||
|
||||||
| 21 | Hepatocyte growth factor receptor signaling | 115 | 0.521 | |||
|
||||||
| 22 | NGF Pathway | 87 | 0.521 | |||
|
||||||
| 23 | MIF Mediated Glucocorticoid Regulation | 681 | 0.521 | |||
|
||||||
| 24 | Endometrial cancer | 201 | 0.521 | |||
|
||||||
| 25 | Presenilin-Mediated Signaling | 142 | 0.521 | |||
|
||||||
| 26 | PI3K-Akt signaling pathway | 390 | 0.521 | |||
|
||||||
| 27 | miRNA regulation of p53 pathway in prostate cancer | 32 | 0.521 | |||
|
||||||
| 28 | ERK Signaling | 1185 | 0.521 | |||
|
||||||
| 29 | TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions | 170 | 0.521 | |||
|
||||||
| 30 | Celecoxib Pathway, Pharmacodynamics | 58 | 0.521 | |||
|
||||||
| 31 | Development EGFR signaling pathway | 154 | 0.521 | |||
|
||||||
| 32 | Nucleotide-binding oligomerization domain (NOD) pathway | 41 | 0.521 | |||
|
||||||
| 33 | Oxidative damage response | 40 | 0.521 | |||
|
||||||
| 34 | NO/cGMP/PKG mediated neuroprotection | 44 | 0.521 | |||
|
||||||
| 35 | VEGF Pathway (Qiagen) | 122 | 0.521 | |||
|
||||||
| 36 | CASP8 activity is inhibited | 57 | 0.521 | |||
|
||||||
| 37 | Immune response IL-23 signaling pathway | 160 | 0.521 | |||
|
||||||
| 38 | Pathogenesis of ALS | 25 | 0.521 | |||
|
||||||
| 39 | Prolactin Signaling | 432 | 0.521 | |||
|
||||||
| 40 | Overview of interferons-mediated signaling pathway | 168 | 0.521 | |||
|
||||||
| 41 | Thyroid hormones production and peripheral downstream signaling effects | 83 | 0.521 | |||
|
||||||
| 42 | p53 Signaling | 117 | 0.521 | |||
|
||||||
| 43 | SMAC (DIABLO) binds to IAPs | 13 | 0.521 | |||
|
||||||
| 44 | CKAP4 signaling pathway map | 108 | 0.521 | |||
|
||||||
| 45 | LT-BetaR Pathway | 56 | 0.521 | |||
|
||||||
| 46 | TNFR1 Pathway | 190 | 0.521 | |||
|
||||||
| 47 | Apoptosis and survival BAD phosphorylation | 112 | 0.521 | |||
|
||||||
| 48 | Apoptosis and survival_Regulation of Apoptosis by Mitochondrial Proteins | 33 | 0.521 | |||
|
||||||
| 49 | NFAT and Cardiac Hypertrophy | 326 | 0.521 | |||
|
||||||
| 50 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 135 | 0.521 | |||
|
||||||
| 51 | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 57 | 0.521 | |||
|
||||||
| 52 | IL-17 Family Signaling Pathways | 108 | 0.521 | |||
|
||||||
| 53 | DREAM Repression and Dynorphin Expression | 250 | 0.521 | |||
|
||||||
| 54 | Ceramide Pathway | 93 | 0.521 | |||
|
||||||
| 55 | Apoptotic Pathways in Synovial Fibroblasts | 731 | 0.521 | |||
|
||||||
| 56 | Development IGF-1 receptor signaling | 110 | 0.521 | |||
|
||||||
| 57 | Integrated breast cancer pathway | 150 | 0.521 | |||
|
||||||
| 58 | Granzyme Pathway | 37 | 0.521 | |||
|
||||||
| 59 | p75(NTR)-mediated signaling | 61 | 0.521 | |||
|
||||||
| 60 | NF-kappaB Pathway | 152 | 0.521 | |||
|
||||||
| 61 | miRNA regulation of DNA damage response | 74 | 0.521 | |||
|
||||||
| 62 | Gemtuzumab ozogamicin Pathway, Pharmacokinetics/Pharmacodynamics | 23 | 0.521 | |||
|
||||||
| 63 | DYRK1A involvement regarding cell proliferation in brain development | 62 | 0.521 | |||
|
||||||
| 64 | Nur77 Signaling in T-Cell | 35 | 0.521 | |||
|
||||||
| 65 | CTL Mediated Apoptosis | 38 | 0.521 | |||
|
||||||
| 66 | Signal Transduction | 2590 | 0.521 | |||
|
||||||
| 67 | Orexin receptor pathway | 24 | 0.521 | |||
|
||||||
| 68 | RAF/MAP kinase cascade | 571 | 0.521 | |||
|
||||||
| 69 | Toll-like receptor signaling pathway | 285 | 0.521 | |||
|
||||||
| 70 | Allograft rejection | 93 | 0.521 | |||
|
||||||
| 71 | Infectious disease | 1747 | 0.521 | |||
|
||||||
| 72 | Innate Immune System | 2025 | 0.521 | |||
|
||||||
| 73 | Androgen receptor network in prostate cancer | 105 | 0.521 | |||
|
||||||
| 74 | Intrinsic Pathway for Apoptosis | 55 | 0.521 | |||
|
||||||
| 75 | Colorectal Cancer Metastasis | 165 | 0.521 | |||
|
||||||
| 76 | Hepatitis C and hepatocellular carcinoma | 55 | 0.521 | |||
|
||||||
| 77 | Corticotropin-releasing hormone signaling pathway | 91 | 0.521 | |||
|
||||||
| 78 | S-1P Stimulated Signaling | 96 | 0.521 | |||
|
||||||